UHPLC/MS Analysis of Antineoplastic and Antidepressant Drugs in Plasma on Titan™ C18 after SPE using HybridSPE®-PLus

UHPLC/MS Analysis of Antineoplastic and Antidepressant Drugs in Plasma on Titan™ C18 after SPE using HybridSPE®-PLus

Conditions

sample preparation final analyte concentration 50 ng/mL
sample/matrix rat plasma
SPE well plate HybridSPE-PLus 96-Well Plate, 50 mg/2 mL per well (575659-U)
sample addition 400 µl of 1% formic acid acetonitile:spiked plasma (3:1) per well
column Titan C18, 5 cm x 2.1 mm I.D., 1.9 µm particles (577122-U)
column temp. 35 C
mobile phase [A] 5 mM ammonium formate; [B] 5 mM ammonium formate in 90:10 (v:v) acetonitrile:water
gradient 35 to 90% B in 1.5 min, held at 90% B for 0.4 min
flow rate 0.4 ml/min
pressure 3582 psi (247 bar)
injection 1 µl
detector TOF/MS

Description

Analysis Note HybridSPE-Phospholipid plates removed plasma-derived proteins and phospholipids to maximize LC/MS sensitivity. Titan C18 U/HPLC columns provided rapid resolution. The highest grade LC-MS solvents were used to supply low background interference and low particulate contaminants for robust, trouble-free operation. Cerilliant CRMs provided reliable identification and quantification.
Categories Analytical Chromatography, SPE Applications, Antineoplastics, Antidepressants
Featured Industry Pharmaceutical (small molecule)
Legal Information HybridSPE is a registered trademark of Sigma-Aldrich Co. LLC, Titan is a trademark of Sigma-Aldrich Co. LLC
suitability application for SPE, application for HPLC

Materials

     
Related Links